Selected article for: "lmwh enoxaparin and low molecular weight heparin"
Author: D’Ardes, Damiano; Carrarini, Claudia; Russo, Mirella; Dono, Fedele; Speranza, Rino; Digiovanni, Anna; Martinotti, Giovanni; Di Iorio, Angelo; Onofrj, Marco; Cipollone, Francesco; Bonanni, Laura
Title: Low molecular weight heparin in COVID-19 patients prevents delirium and shortens hospitalization
  • Cord-id: snnpfqik
  • Document date: 2020_11_13
    • ID: snnpfqik
    Snippet: BACKGROUND: COVID-19 patients present with delirium during their hospitalization. AIMS: To assess the incidence of delirium in hospitalized COVID-19 patients and analyze the possible association with demographic, clinical, laboratory, and pharmacological factors. METHODS: COVID-19 patients were assessed for clinical signs of delirium and administered the assessment test for delirium and cognitive impairment (4AT) and the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) scales. R
    Document: BACKGROUND: COVID-19 patients present with delirium during their hospitalization. AIMS: To assess the incidence of delirium in hospitalized COVID-19 patients and analyze the possible association with demographic, clinical, laboratory, and pharmacological factors. METHODS: COVID-19 patients were assessed for clinical signs of delirium and administered the assessment test for delirium and cognitive impairment (4AT) and the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) scales. RESULTS: Out of the 56 patients of our cohort, 14 (25.0%) experienced delirium. The use of low molecular weight heparin (LMWH) (enoxaparin 1 mg/kg/daily) was less frequent in patients with delirium (p = 0.004) and was accompanied by lower C reactive protein (CRP) levels (p = 0.006). DISCUSSION: The use of LMWH was associated with absence of delirium, independently of comorbidities and age. CONCLUSIONS: The use of LMWH may help preventing the occurrence of delirium in COVID-19 patients, with possible reduction of length of stay in the hospital and sequelae. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10072-020-04887-4.

    Search related documents:
    Co phrase search for related documents
    • absence presence and acute phase: 1, 2, 3, 4, 5, 6, 7, 8
    • absence presence and acute phase protein: 1
    • absence presence and logistic model: 1, 2, 3, 4, 5, 6, 7
    • absence presence and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • absence presence and logistic regression analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • absence presence and los stay hospital length: 1, 2
    • absence presence study and logistic regression: 1
    • absolute number and acute phase: 1
    • absolute number and logistic model: 1
    • absolute number and logistic regression: 1, 2, 3, 4, 5
    • absolute number and logistic regression analysis: 1
    • active cancer and acute phase: 1, 2
    • active cancer and logistic model: 1, 2, 3, 4, 5
    • active cancer and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • active cancer and logistic regression analysis: 1, 2, 3, 4, 5, 6
    • active cancer and los stay hospital length: 1, 2
    • acute phase and logistic regression analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute phase and long term cognitive impairment: 1
    • acute phase and los stay hospital length: 1